ClinicalTrials.gg
CompletedNCT00538902Updated Apr 11, 2011Results posted

Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

A Phase 2/3 interventional study of Placebo and Adalimumab 80 mg in Rheumatoid Arthritis, sponsored by Abbott. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
31st of 87
302 · median 160
Started
2007
with 6 others
Phase 2/3
3 of 87
none open now
Registered
20th of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 31st largest by enrollment, is one of 7 that started in 2007, is one of 3 in phase 2/3, and was the 20th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A study to assess the safety and efficacy of adalimumab administered as a subcutaneous injection in adult Chinese subjects with rheumatoid arthritis and treated with methotrexate

Read the detailed description

This was a multi-center, Phase 2/3, randomized, double-blind (DB), parallel group, placebo controlled, safety and efficacy study in adult Chinese RA subjects. The duration of the study was approximately 116 weeks. This included a 4-week (28 days) Screening period, a 12-week Double-Blind (DB) period, a 90-week Open-Label (OL) Period, and a 10-week (70 days) Follow-up period. The 70-day Safety Follow-up period was initiated after the last dose of study medication.

During the DB period, 302 Chinese subjects with RA and concomitantly treated with MTX were enrolled at 11 clinical sites located throughout China. Subjects were randomly assigned to one of the three treatment groups in a 2:2:1 ratio: 80 mg adalimumab, 40 mg adalimumab, or placebo. From Week 0 to Week 10, subjects received blinded study drug. Subjects who successfully participated and completed Week 12 of the DB portion of the study participated in the OL period. All subjects in the OL period received adalimumab 40 mg. Throughout the study, the study drug was administered subcutaneously (SC) every other week (eow).

Subjects that completed the Week 24 visit, prior to the approval of Protocol Amendment 1, had 70 days from the last dose of study drug to re-enter the study. The Investigator confirmed that the subject did not develop any of the exclusion criteria and completed the procedures defined by the OL Screening visit.

Results through Week 24 of this study were presented in the regulatory dossier for the marketing authorization application of Humira in China, fulfilling the requirement for clinical data in Chinese patients. However, in order to continue to provide treatment to patients who responded well to adalimumab, subjects had the option to continue in the OL extension of this study until Week 92.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Humira, methotrexate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Met ACR criteria for diagnosis of active rheumatoid arthritis (RA) and have had at both the Screening visit and Week 0 visit at least four swollen joints (out of 66 assessed) and at least six tender joints(out of 68 assessed)
  • Subjects must have failed prior treatment with one or more disease-modifying antirheumatic drugs (DMARDs)
  • DMARDs (other than methotrexate [MTX]) must have been discontinued for >= 28 days or at least 5 half-lives, whichever is greater, before the Week 0 visit
  • Traditional Chinese Medicines must have been discontinued for >= 28 days before the Week 0 visit
  • Subjects must have received at least three months of treatment with MTX (minimum 7.5 mg/week) and remained on a stable dose of MTX for >= 28 days prior to the Screening visit
  • equivalent to \<= 10 mg of prednisone and prednisone equivalent must have remained unchanged for at least 28 days prior to the Week 0 visit
  • Must have been able and willing to give written and to comply with the requirements of this study protocol

Exclusion criteria

Exclusion Criteria:

  • A history of, or current, acute inflammatory joint disease of different origin (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, fibromyalgia or any arthritide with onset prior to age 16 years
  • Wheelchair-bound or bedridden
  • Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit
  • Intra-articular, intramuscular or intravenous administration of within 28 days prior to the Screening visit
  • Prior treatment with any TNF antagonist, including adalimumab
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously every other week

    Biological: Placebo

  • Experimental
    Adalimumab 80 mg

    Adalimumab 80 mg administered subcutaneously every other week

    Biological: Adalimumab 80 mg

  • Experimental
    Adalimumab 40 mg

    Adalimumab 40 mg administered subcutaneously every other week

    Biological: Adalimumab 40 mg

Interventions

  • BiologicalPlacebo

    Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

  • Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

    Also known as: Humira

  • Adalimumab 40 mg administered subcutaneously every other week for 104 weeks

    Also known as: Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period

    American College of Rheumatology (ACR) criteria improvement consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-Blind period.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Achieving American College of Rheumatology (ACR)50/70 at Week 12 of the Double-Blind Period

    American College of Rheumatology (ACR) criteria improvement consisting of 50% or 70% (ACR50/70) reduction in tender or swollen joint counts and 50% or 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-blind period.

    Time frame: Week 12

  2. Number of Participants Achieving American College of Rheumatology (ACR)20 Response Through Week 92 of Open-Label Period

    American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  3. Number of Participants Achieving American College of Rheumatology (ACR)50 Response Through Week 92 of Open-Label Period

    American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 50% (ACR50) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  4. Number of Participants Achieving American College of Rheumatology (ACR)70 Response Through Week 92 of Open-Label Period

    American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 70% (ACR70) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  5. Mean Change in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12 of the Double-Blind Period

    Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

    Time frame: Baseline, Week 12

  6. Mean Change in Tender Joint Count (TJC) Through Week 92 of the Open-Label Period

    Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  7. Mean Change in Swollen Joint Count (SJC) Through Week 92 of the Open-Label Period

    Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  8. Mean Change in Visual Analog Scale (VAS) Score at Week 12 of the Double-Blind Period

    Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state. Week 12 = end of Double-Blind period.

    Time frame: Baseline, Week 12

  9. Mean Change in Physician's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

    Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  10. Mean Change in Patient's Assessment of Pain (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

    Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  11. Mean Change in Patient's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

    Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  12. Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period

    HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index = improvement in disease (0 = no difficulties). Week 12 = end of Double-Blind period.

    Time frame: Baseline, Week 12

  13. Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Through Week 92 of the Open-Label Period

    HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index indicates an improvement in disease (0 = no difficulties).

    Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  14. Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) and Mental Component Summary (MCS) at Week 12 of the Double-Blind Period

    SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

    Time frame: Baseline, Week 12

  15. Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) Through Week 92 of the Open-Label Period

    SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

    Time frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

  16. Mean Change in the SF-36 Health Survey Index Mental Component Summary (MCS) Through Week 92 of the Open-Label Period

    SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

    Time frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92

07

Results

Posted Dec 30, 2009

Participant flow

DB Wk 0 Through 12 (Primary D/C Reasons)
Participant flow — DB Wk 0 Through 12 (Primary D/C Reasons)
MilestonePlaceboAdalimumab 40 mgAdalimumab 80 mg
Started60121121
Completed59119116
Not completed125
Withdrew: Adverse event123
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up001
Withdrew: Various000
OL Wk 24 to End (Primary D/C Reasons)
Participant flow — OL Wk 24 to End (Primary D/C Reasons)
MilestonePlaceboAdalimumab 40 mgAdalimumab 80 mg
Started59119116
Completed235552
Not completed366464
Withdrew: Adverse event21011
Withdrew: Withdrawal by subject151925
Withdrew: Lost to follow-up1106
Withdrew: Various182522

Outcome measures

PrimaryNumber of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period

American College of Rheumatology (ACR) criteria improvement consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-Blind period.

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period
ParticipantsPlaceboAdalimumab 40 mgAdalimumab 80 mg
Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period216962
Statistical analysis
  • Placebo vs Adalimumab 80 mg · Cochran-Mantel-Haenszel · p = 0.026 (Each comparison was tested at the 2-sided alpha level of 0.05. Subjects with missing data were imputed to be non-responders. The overall type I error rate was preserved by a hierarchical stepwise closed testing procedure.) · Odds ratio (or): 2.19 · 95% CI 1.09 to 4.39
  • Placebo vs Adalimumab 40 mg · Cochran-Mantel-Haenszel · p = 0.004 (Each comparison was tested at the 2-sided alpha level of 0.05. Subjects with missing data were imputed to be non-responders. The overall type I error rate was preserved by a hierarchical stepwise closed testing procedure.) · Odds ratio (or): 2.68 · 95% CI 1.35 to 5.30
SecondaryNumber of Participants Achieving American College of Rheumatology (ACR)50/70 at Week 12 of the Double-Blind Period

American College of Rheumatology (ACR) criteria improvement consisting of 50% or 70% (ACR50/70) reduction in tender or swollen joint counts and 50% or 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-blind period.

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants Achieving American College of Rheumatology (ACR)50/70 at Week 12 of the Double-Blind Period
ParticipantsPlaceboAdalimumab 40 mgAdalimumab 80 mg
ACR5093929
ACR7021911
Statistical analysis
  • Placebo vs Adalimumab 40 mg · Cochran-Mantel-Haenszel · p = 0.009 (The between-treatment comparison between each adalimumab group vs. placebo was performed at the 2-sided alpha = 0.05 significance level, without using a stepwise testing procedure or alpha adjustment.)Percentage ACR responders at Week 12 were compared between adalimumab and placebo groups, where missing ACR responses were imputed as non-responder.
  • Placebo vs Adalimumab 80 mg · Cochran-Mantel-Haenszel · p = 0.121
SecondaryNumber of Participants Achieving American College of Rheumatology (ACR)20 Response Through Week 92 of Open-Label Period

American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Number · Participants
Number of Participants Achieving American College of Rheumatology (ACR)20 Response Through Week 92 of Open-Label Period
ParticipantsAll Open-Label Adalimumab
Week 0 Responders (n = 293)152
Week 4 Responders (n = 289)179
Week 8 Responders (n = 283)183
Week 12 Responders (n = 279)207
Week 24 Responders (n = 208)153
Week 36 Responders (n = 200)158
Week 48 Responders (n = 183)147
Week 60 Responders (n = 166)131
Week 72 Responders (n = 150)108
Week 84 Responders (n = 137)111
Week 92 Responders (n = 130)105
SecondaryNumber of Participants Achieving American College of Rheumatology (ACR)50 Response Through Week 92 of Open-Label Period

American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 50% (ACR50) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Number · Participants
Number of Participants Achieving American College of Rheumatology (ACR)50 Response Through Week 92 of Open-Label Period
ParticipantsAll Open-Label Adalimumab
Week 0 Responders (n = 293)77
Week 4 Responders (n = 289)95
Week 8 Responders (n = 283)103
Week 12 Responders (n = 279)119
Week 24 Responders (n = 208)96
Week 36 Responders (n = 200)102
Week 48 Responders (n = 183)94
Week 60 Responders (n = 166)74
Week 72 Responders (n = 150)79
Week 84 Responders (n = 137)74
Week 92 Responders (n = 130)69
SecondaryNumber of Participants Achieving American College of Rheumatology (ACR)70 Response Through Week 92 of Open-Label Period

American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 70% (ACR70) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Number · Participants
Number of Participants Achieving American College of Rheumatology (ACR)70 Response Through Week 92 of Open-Label Period
ParticipantsAll Open-Label Adalimumab
Week 0 Responders (n = 293)32
Week 4 Responders (n = 289)39
Week 8 Responders (n = 283)49
Week 12 Responders (n = 279)52
Week 24 Responders (n = 208)39
Week 36 Responders (n = 200)48
Week 48 Responders (n = 183)40
Week 60 Responders (n = 166)37
Week 72 Responders (n = 150)30
Week 84 Responders (n = 137)38
Week 92 Responders (n = 130)34
SecondaryMean Change in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12 of the Double-Blind Period

Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

Time frame:
Baseline, Week 12
Reported as:
Mean · Joints
Mean Change in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12 of the Double-Blind Period
JointsPlaceboAdalimumab 40 mgAdalimumab 80 mg
TJC Week 12-7.0 ± 12.1-12.2 ± 14.9-8.8 ± 12.6
SJC Week 12-4.7 ± 8.7-8.6 ± 8.6-6.4 ± 6.6
SecondaryMean Change in Tender Joint Count (TJC) Through Week 92 of the Open-Label Period

Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · Joints
Mean Change in Tender Joint Count (TJC) Through Week 92 of the Open-Label Period
JointsAll Open-Label Adalimumab
Baseline22.8 ± 16.07
Week 0 (n = 293)-9.9 ± 13.44
Week 4 (n = 289)-12.3 ± 13.08
Week 8 (n = 283)-13.4 ± 13.68
Week 12 (n = 279)-14.4 ± 14.15
Week 24 (n = 208)-16.4 ± 13.54
Week 36 (n = 200)-16.5 ± 13.57
Week 48 (n = 183)-17.6 ± 14.24
Week 60 (n = 166)-17.0 ± 13.99
Week 72 (n = 150)-18.0 ± 14.15
Week 84 (n = 137)-18.5 ± 15.18
Week 92 (n = 130)-18.0 ± 14.23
SecondaryMean Change in Swollen Joint Count (SJC) Through Week 92 of the Open-Label Period

Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · Joints
Mean Change in Swollen Joint Count (SJC) Through Week 92 of the Open-Label Period
JointsAll Open-Label Adalimumab
Baseline11.2 ± 7.74
Week 0 (n = 293)-6.9 ± 8.03
Week 4 (n = 289)-7.4 ± 8.87
Week 8 (n = 283)-8.3 ± 8.16
Week 12 (n = 279)-8.8 ± 7.87
Week 24 (n = 208)-9.3 ± 8.62
Week 36 (n = 200)-9.3 ± 8.41
Week 48 (n = 183)-9.7 ± 8.45
Week 60 (n = 166)-9.0 ± 7.95
Week 72 (n = 150)-9.2 ± 7.90
Week 84 (n = 137)-9.5 ± 7.99
Week 92 (n = 130)-9.5 ± 8.00
SecondaryMean Change in Visual Analog Scale (VAS) Score at Week 12 of the Double-Blind Period

Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state. Week 12 = end of Double-Blind period.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm
Mean Change in Visual Analog Scale (VAS) Score at Week 12 of the Double-Blind Period
mmPlaceboAdalimumab 40 mgAdalimumab 80 mg
PhGA, Week 12-20.6 ± 19.1-25.1 ± 22.7-20.9 ± 19.7
Pain, Week 12-14.9 ± 26-22.7 ± 25.2-16.4 ± 22.4
PGA, Week 12-13.8 ± 26.2-23.6 ± 25.2-16.3 ± 25.5
SecondaryMean Change in Physician's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · mm
Mean Change in Physician's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
mmAll Open-Label Adalimumab
Baseline60.1 ± 16.40
Week 0 (n = 293)-22.8 ± 20.67
Week 4 (n = 289)-25.5 ± 21.27
Week 8 (n = 283)-28.3 ± 22.17
Week 12 (n = 279)-31.3 ± 21.15
Week 24 (n = 208)-30.7 ± 20.88
Week 36 (n = 200)-33.6 ± 21.03
Week 48 (n = 183)-33.5 ± 20.58
Week 60 (n = 166)-32.6 ± 21.86
Week 72 (n = 150)-32.6 ± 22.26
Week 84 (n = 137)-33.8 ± 20.99
Week 92 (n = 130)-35.0 ± 19.02
SecondaryMean Change in Patient's Assessment of Pain (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · mm
Mean Change in Patient's Assessment of Pain (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
mmAll Open-Label Adalimumab
Baseline60.5 ± 19.19
Week 0 (n = 293)-18.7 ± 23.96
Week 4 (n = 289)-21.1 ± 24.55
Week 8 (n = 283)-23.3 ± 26.25
Week 12 (n = 279)-27.1 ± 24.34
Week 24 (n = 208)-25.4 ± 23.46
Week 36 (n = 200)-27.4 ± 24.86
Week 48 (n = 183)-27.0 ± 25.81
Week 60 (n = 166)-28.0 ± 26.54
Week 72 (n = 150)-26.4 ± 28.14
Week 84 (n = 137)-27.8 ± 24.71
Week 92 (n = 130)-27.1 ± 25.41
SecondaryMean Change in Patient's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period

Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · mm
Mean Change in Patient's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
mmAll Open-Label Adalimumab
Baseline60.7 ± 19.61
Week 0 (n = 293)-19.0 ± 25.18
Week 4 (n = 289)-21.0 ± 26.19
Week 8 (n = 283)-23.6 ± 26.88
Week 12 (n = 279)-26.3 ± 25.79
Week 24 (n = 208)-26.6 ± 25.13
Week 36 (n = 200)-29.8 ± 25.32
Week 48 (n = 183)-30.5 ± 26.02
Week 60 (n = 166)-28.7 ± 28.38
Week 72 (n = 150)-28.7 ± 25.98
Week 84 (n = 137)-30.5 ± 25.62
Week 92 (n = 130)-29.6 ± 25.04
SecondaryMean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period

HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index = improvement in disease (0 = no difficulties). Week 12 = end of Double-Blind period.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period
score on a scalePlaceboAdalimumab 40 mgAdalimumab 80 mg
Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period-0.3 ± 0.7-0.5 ± 0.5-0.4 ± 0.6
SecondaryMean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Through Week 92 of the Open-Label Period

HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index indicates an improvement in disease (0 = no difficulties).

Time frame:
Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · score on a scale
Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Through Week 92 of the Open-Label Period
score on a scaleAll Open-Label Adalimumab
Baseline1.38 ± 0.692
Week 0 (n = 293)-0.42 ± 0.575
Week 4 (n = 289)-0.51 ± 0.584
Week 8 (n = 283)-0.55 ± 0.621
Week 12 (n = 279)-0.61 ± 0.620
Week 24 (n = 208)-0.56 ± 0.617
Week 36 (n = 200)-0.58 ± 0.609
Week 48 (n = 183)-0.60 ± 0.622
Week 60 (n = 166)-0.65 ± 0.631
Week 72 (n = 150)-0.65 ± 0.603
Week 84 (n = 137)-0.63 ± 0.590
Week 92 (n = 130)-0.62 ± 0.591
SecondaryMean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) and Mental Component Summary (MCS) at Week 12 of the Double-Blind Period

SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) and Mental Component Summary (MCS) at Week 12 of the Double-Blind Period
score on a scalePlaceboAdalimumab 40 mgAdalimumab 80 mg
Physical Component Score, Week 124.2 ± 7.15.7 ± 7.34.5 ± 7.6
Mental Component Score, Week 123.5 ± 11.84.9 ± 10.72.5 ± 12.1
SecondaryMean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) Through Week 92 of the Open-Label Period

SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

Time frame:
Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · score on a scale
Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) Through Week 92 of the Open-Label Period
score on a scaleAll Open-Label Adalimumab
Baseline32.14 ± 7.759
Week 0 (n = 293)5.01 ± 7.356
Week 12 (n = 283)7.15 ± 8.225
Week 24 (n = 208)6.8 ± 7.251
Week 36 (n = 200)7.96 ± 7.478
Week 48 (n = 183)8.17 ± 8.046
Week 60 (n = 166)8.29 ± 7.666
Week 72 (n = 150)7.77 ± 8.806
Week 84 (n = 137)8.38 ± 8.182
Week 92 (n = 130)8.49 ± 8.195
SecondaryMean Change in the SF-36 Health Survey Index Mental Component Summary (MCS) Through Week 92 of the Open-Label Period

SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.

Time frame:
Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Reported as:
Mean · score on a scale
Mean Change in the SF-36 Health Survey Index Mental Component Summary (MCS) Through Week 92 of the Open-Label Period
score on a scaleAll Open-Label Adalimumab
Baseline36.50 ± 10.894
Week 0 (n = 293)3.74 ± 11.494
Week 12 (n = 283)5.73 ± 12.686
Week 24 (n = 208)5.22 ± 11.699
Week 36 (n = 200)5.51 ± 11.268
Week 48 (n = 183)5.29 ± 11.285
Week 60 (n = 166)5.56 ± 10.716
Week 72 (n = 150)4.75 ± 10.825
Week 84 (n = 137)5.09 ± 11.998
Week 92 (n = 130)4.14 ± 11.867

Adverse events

Collected over The duration for adverse event reporting was 92 weeks. Data from the Double-Blind period (Week 0 through Week 12) and from any adalimumab exposure (Week 0 through Week 92) were reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Phase - Placebo EOW—0/60 (0%)11/60 (18.3%)
DB Phase - Adalimumab 40 mg EOW—0/121 (0%)30/121 (24.8%)
DB Phase - Adalimumab 80 mg EOW—3/121 (2.5%)27/121 (22.3%)
Any Adalimumab—23/301 (7.6%)84/301 (27.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventDB Phase - Placebo EOWDB Phase - Adalimumab 40 mg EOWDB Phase - Adalimumab 80 mg EOWAny Adalimumab
Pulmonary tuberculosisInfections and infestations0/600/1210/1215/301
Cerebral hemorrhageNervous system disorders0/600/1211/1211/301
Femoral neck fractureInjury, poisoning and procedural complications0/600/1211/1211/301
Hypertensive crisisVascular disorders0/600/1211/1211/301
Lymph node painBlood and lymphatic system disorders0/600/1211/1211/301
LymphadenopathyBlood and lymphatic system disorders0/600/1211/1211/301
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/600/1211/1210/301
Acute myocardial infarctionCardiac disorders0/600/1210/1212/301
Disseminated tuberculosisInfections and infestations0/600/1210/1212/301
PneumoniaInfections and infestations0/600/1210/1212/301
Most frequent other events
Most frequent other events
EventDB Phase - Placebo EOWDB Phase - Adalimumab 40 mg EOWDB Phase - Adalimumab 80 mg EOWAny Adalimumab
Upper respiratory tract infectionInfections and infestations7/6017/12115/12160/301
NasopharyngitisInfections and infestations4/607/1219/12132/301
Injection site pruritusGeneral disorders0/607/1215/1210/301

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboAdalimumab 40 mgAdalimumab 80 mgTotal
<=18 years0000
Between 18 and 65 years58115111284
>=65 years261018
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab 40 mgAdalimumab 80 mgTotal
Female49104101254
Male11172048
Region of Enrollment
Region of Enrollment(participants)PlaceboAdalimumab 40 mgAdalimumab 80 mgTotal
China60121121302
08

Study locations

11 sites
  • Site Reference ID/Investigator# 6259
    Hefei, Anhui 230022, China
  • Site Reference ID/Investigator# 6266
    Beijing, 100730, China
  • Site Reference ID/Investigator# 6241
    Beijing, 100853, China
  • Site Reference ID/Investigator# 6243
    Guangzhou, 510260, China
  • Site Reference ID/Investigator# 6247
    Guangzhou, 510630, China
  • Site Reference ID/Investigator# 6262
    Harbin, 150001, China
  • Site Reference ID/Investigator# 6248
    Hepingjiebeikou, 100029, China
  • Site Reference ID/Investigator# 6250
    Shanghai, 200001, China
  • Site Reference ID/Investigator# 6828
    Shanghai, 200032, China
  • Site Reference ID/Investigator# 6333
    Shanghai, 200433, China
  • Site Reference ID/Investigator# 6264
    Xi'an, 710032, China
09

References and documents

Publications

  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2007
First posted
Oct 3, 2007
Start
Aug 2007
Primary completionActual
Jul 2008
CompletionActual
Dec 2009
Results first posted
Dec 30, 2009
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00538902
Lead sponsor
Abbott
First posted
Oct 3, 2007
Start date
Aug 2007
Primary completion
Jul 2008
Completion
Dec 2009
Results posted
Dec 30, 2009
Last update
Apr 11, 2011

Study contacts

Laura Redden, MD, PhD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion